247 related articles for article (PubMed ID: 35779497)
41. Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics.
Qi D; Jia B; Peng H; He J; Pi J; Guo P; Zhang Y; Deng X; Li J; Liu Z
Eur J Pharm Biopharm; 2023 Jul; 188():243-253. PubMed ID: 37224929
[TBL] [Abstract][Full Text] [Related]
42. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
[TBL] [Abstract][Full Text] [Related]
43. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
[TBL] [Abstract][Full Text] [Related]
44. State of the art and new perspectives on dry powder inhalers.
Terzano C; Colombo P
Eur Rev Med Pharmacol Sci; 1999; 3(6):247-54. PubMed ID: 11261735
[TBL] [Abstract][Full Text] [Related]
45. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
46. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
47. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
48. Dry powder inhalation, part 2: the present and future.
de Boer AH; Hagedoorn P; Grasmeijer F
Expert Opin Drug Deliv; 2022 Sep; 19(9):1045-1059. PubMed ID: 35984322
[TBL] [Abstract][Full Text] [Related]
49. [A novel pulmonary delivery system--dry powder inhalers].
Tang Y; Zhu JB; Chen XJ
Yao Xue Xue Bao; 2009 Jun; 44(6):571-4. PubMed ID: 19806884
[TBL] [Abstract][Full Text] [Related]
50. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
51. Antitubercular inhaled therapy: opportunities, progress and challenges.
Pandey R; Khuller GK
J Antimicrob Chemother; 2005 Apr; 55(4):430-5. PubMed ID: 15761077
[TBL] [Abstract][Full Text] [Related]
52. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment.
Panigone S; Sandri F; Ferri R; Volpato A; Nudo E; Nicolini G
BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32238349
[TBL] [Abstract][Full Text] [Related]
53. Particulate pulmonary delivery systems containing anti-tuberculosis agents.
Gupta A; Pandya SM; Mohammad I; Agrawal AK; Mohan M; Misra A
Crit Rev Ther Drug Carrier Syst; 2013; 30(4):277-91. PubMed ID: 23662603
[TBL] [Abstract][Full Text] [Related]
54. A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.
Pitner RA; Durham PG; Stewart IE; Reed SG; Cassell GH; Hickey AJ; Carter D
J Pharm Sci; 2019 Oct; 108(10):3302-3311. PubMed ID: 31152746
[TBL] [Abstract][Full Text] [Related]
55. Dosing challenges in respiratory therapies.
Yeung S; Traini D; Lewis D; Young PM
Int J Pharm; 2018 Sep; 548(1):659-671. PubMed ID: 30033395
[TBL] [Abstract][Full Text] [Related]
56. Practical problems with aerosol therapy in COPD.
Rau JL
Respir Care; 2006 Feb; 51(2):158-72. PubMed ID: 16441960
[TBL] [Abstract][Full Text] [Related]
57. Preparation and Evaluation of Low-Dose Calcitriol Dry Powder Inhalation as Host-Directed Adjunct Therapy for Tuberculosis.
Reddy DVS; Shafi H; Bharti R; Roy T; Verma S; Raman SK; Verma K; Azmi L; Ray L; Singh J; Singh AK; Mugale MN; Misra A
Pharm Res; 2022 Oct; 39(10):2621-2633. PubMed ID: 35962268
[TBL] [Abstract][Full Text] [Related]
58. Asthma and chronic obstructive pulmonary disease inhalers: Techniques for proper use.
Pepper AN; Cooke A; Livingston L; Lockey RF
Allergy Asthma Proc; 2016 Jul; 37(4):279-90. PubMed ID: 27401315
[TBL] [Abstract][Full Text] [Related]
59. Spray drying: Inhalable powders for pulmonary gene therapy.
Munir M; Jena L; Kett VL; Dunne NJ; McCarthy HO
Biomater Adv; 2022 Feb; 133():112601. PubMed ID: 35527158
[TBL] [Abstract][Full Text] [Related]
60. Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization,
Acosta MF; Muralidharan P; Grijalva CL; Abrahamson MD; Hayes D; Fineman JR; Black SM; Mansour HM
Ther Adv Respir Dis; 2021; 15():1753466621998245. PubMed ID: 33719747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
